Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update
November 05, 2019 16:01 ET
|
Eloxx Pharmaceuticals
-Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cystinosis this quarter, preliminary...
Eloxx Pharmaceuticals Presents Positive Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)
October 31, 2019 12:15 ET
|
Eloxx Pharmaceuticals
Eloxx presented findings from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies and additional preclinical data for ELX-02 Eloxx will provide an update on the Phase 2...
Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019
October 10, 2019 08:41 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial
September 23, 2019 07:30 ET
|
Eloxx Pharmaceuticals
CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis Eloxx plans to conduct the U.S. portion of the Phase 2 clinical trial at Cystic...
Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019
September 16, 2019 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases on September 24, 2019
September 10, 2019 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 5th, 2019
August 26, 2019 09:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019
August 13, 2019 10:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update
August 07, 2019 07:30 ET
|
Eloxx Pharmaceuticals
Phase 2 cystic fibrosis clinical trial IND is open in the U.S., protocol endorsed by the Cystic Fibrosis Foundation (CFF) Initiated a Phase 2 clinical trial for ELX-02 in cystinosis in Canada and...
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis
August 05, 2019 08:00 ET
|
Eloxx Pharmaceuticals
Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the principal investigator in the Phase 2 clinical trial On track to report top...